Increasing spread of preeclampsia worldwide will be the key driver of the global preeclampsia therapeutics market growth during the forecast period. Preeclampsia refers to a condition wherein a woman experiences high blood pressure during or after pregnancy. There may also occur low clotting factors, indicating problems of the liver or kidneys. The most potential causes identified by doctors for this condition are autoimmune disorders, genetic factors, and blood vessel issues. According to the Maternal Health Task Force under the Harvard Chan School, preeclampsia kills around 76,000 mothers and 500,000 babies globally every year. Moreover, in low and middle income countries, preeclampsia causes 16% of maternal deaths. This rising prevalence of the disorder will spur the demand for preeclampsia therapeutics and favor the growth of the global preeclampsia therapeutics market in the forecast period.
Rising Incidence of Hypertension to Boost the Market
Close links have been established between hypertension (high blood pressure) and onset of preeclampsia. Women who have been suffering from chronic hypertension before pregnancy are more prone to developing preeclampsia during pregnancy. Hypertension has been on the rise worldwide. According to the World Health Organization (WHO), currently, around 1.13 billion are suffering from hypertension globally. The American Heart Association estimates that close to 50% of Americans are affected by hypertension. Thus, higher prevalence of hypertension is a major risk factor for preeclampsia, which will push up the demand for preeclampsia therapeutics till 2026. Furthermore, hypertension can also induce gestational diabetes in pregnant women, which, in turn, can cause the development of preeclampsia. This might lead to premature delivery of the baby and can cause stroke or seizure during labour and delivery. As diabetes becomes more prevalent, preeclampsia might become more common and lead to the expansion of the global preeclampsia therapeutics market size.
Fortune Business Insights identifies some of the major competitors in the global preeclampsia therapeutics market:
- Hoffmann-La Roche Ltd.
- Sera Prognostics
- Pluristem Therapeutics Inc.
- DRG INSTRUMENTS GmbH
- AMAG Pharmaceuticals
- A1M Pharma AB
- PerkinElmer Inc.
- VG Lifesciences
More Trending Topics From Fortune Business [email protected]